{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109744","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.329460+00:00","generated_at":"2026-05-16T20:59:44.419835+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Milestone reports Q3 net loss $11.9M; PDUFA target Dec 13 for CARDAMYST in PSVT","bullets":["Cash, equivalents and short-term investments $82.6M at Sept 30, up from $69.7M at Dec 31, 2024.","Net loss Q3 $11.9M vs $9.4M a year ago; no revenue reported in either period.","Commercial expense surged to $4.6M (Q3) from $1.9M on launch prep for potential FDA approval.","NDA for CARDAMYST (etripamil) under FDA review; PDUFA action date December 13, 2025.","Completed $48.7M equity offering and amended Royalty Purchase Agreement securing $75M upon approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109744","json":"https://secwatch.observer/filing/0001104659-25-109744.json","markdown":"https://secwatch.observer/filing/0001104659-25-109744.md","text":"https://secwatch.observer/filing/0001104659-25-109744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/0001104659-25-109744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/tm2530945d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:59:44.419835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}